bioRxivCancer BiologyPreprint
BLTP3A dysfunction unleashes lysosomal stress-induced antitumor immunity through STING
Elaheh Sadat HosseiniiD, Steven Wang, Mona ArabzadehiD, Kristen E. Warrington, Maria T. SøgaardiD, Amartya SinghiD, Wenjin Chen, Lomaani Ranasinghe, Rinkee Kumari, Christopher Alcott, Adam RobinsoniD, Shreya YadaviD, Wenwei Hu, Jian Cao, Eugenia GirdaiD, Eileen WhiteiD, Christian S. HinrichsiD, Kyle Kristopher Payne
Abstract
High-grade serous ovarian cancer progresses within a lipid-rich ascites microenvironment that engages stress-adaptation programs supporting malignant growth, yet how failed stress resolution influences tumor progression remains incompletely defined. Here, we show that unresolved lysosomal stress restrains tumor progression by sustaining tumor cell-intrinsic STING activity and reorganizing antitumor immunity. We identify BLTP3A as a lysosomal stress-resolution factor in ovarian cancer and show that the common germline missense variant BLTP3A M1098T increases stress-induced lysosomal damage. Patients carrying M1098T had longer overall survival and tumors enriched for cytotoxic T cell-myeloid neighborhoods. In syngeneic tumors, Bltp3a loss or orthologous variant expression delayed progression and generated Cxcl9+ antigen-presenting macrophage niches; M1098T-expressing human tumors similarly promoted interferon-responsive myeloid and T-cell enrichment in humanized mice. Mechanistically, ascites-induced lysosomal stress activated a STING-ATF4-BLTP3A feedback program. BLTP3A dysfunction disrupted CASM-associated lysosomal stress resolution, resulting in prolonged STING activity and sustained tumor-derived IFN-{lambda} without increased cGAMP. Tumor-cell STING and IFN-{lambda} were required for immune remodeling and tumor control. Thus, BLTP3A-dependent lysosomal stress resolution constrains the persistence of stress-induced STING signaling, whereas failure of this response sustains a tumor-intrinsic inflammatory program that organizes protective antitumor immunity.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- assay: proteomics
- research focus: cell-cell communication
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- FSTL3 is a biomarker of poor prognosis and is associated with immunotherapy resistance in ovarian cancer.
Maeva Y. Chauvin, Estelle Tromelin, … David Pépin·Journal of Experimental & Clinical Cancer ResearchPeer-reviewed·Sep 30, 2025
- Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness
Z. Huang, O. Byrd, … S. K. Murphy·bioRxiv·Mar 30, 2023
- Targeting Tumor Immunity: Statins as a Repurposed Strategy for Preventing Ovarian Cancer Advancement
Juliane Marie Liberto, Sumeng Qi, … Tian‐Li Wang·bioRxiv·Sep 16, 2026
- Tertiary lymphoid structures induced by CXCL13-producing CD4+ T cells increase tumor infiltrating CD8+ T cells and B cells in ovarian cancer
M. Ukita, J. Hamanishi, … M. Mandai·JCI InsightPeer-reviewed·Jun 22, 2022
- Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
K. G. Anderson, S. K. Oda, … P. D. Greenberg·bioRxiv·Jul 30, 2021
- PVT1, a YAP1 dependent stress responsive lncRNA drives ovarian cancer metastasis and chemoresistance
K. Tabury, M. Monavarian, … K. Mythreye·bioRxiv·Jan 11, 2022